Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

PURPOSE: SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133–tositumomab radioimmunotherapy) for previously untreated pati...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Shadman, Mazyar, Li, Hongli, Rimsza, Lisa, Leonard, John P., Kaminski, Mark S., Braziel, Rita M., Spier, Catherine M., Gopal, Ajay K., Maloney, David G., Cheson, Bruce D., Dakhil, Shaker, LeBlanc, Michael, Smith, Sonali M., Fisher, Richard I., Friedberg, Jonathan W., Press, Oliver W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553811/
https://ncbi.nlm.nih.gov/pubmed/29356608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.74.5083
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi